Tenaya Therapeutics, Inc.
TNYATenaya Therapeutics is a clinical-stage biotechnology company focused on discovering and developing potentially curative therapies for heart disease.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering and developing potentially curative therapies for heart disease. The company utilizes a modality-agnostic approach, leveraging human genetics and disease models to target the underlying drivers of both rare genetic cardiomyopathies and prevalent cardiovascular conditions. Its core value proposition is built on an integrated platform combining gene therapy, small molecule development, and internal manufacturing capabilities.
Tenaya is a clinical-stage innovator in precision cardiology, distinguished by its integrated AAV engineering and manufacturing capabilities. It competes by targeting specific genetic drivers of heart disease where few disease-modifying treatments currently exist.
Questions, answered.
- What is Tenaya Therapeutics, Inc.'s market cap?
- Tenaya Therapeutics, Inc. (TNYA) has a market capitalization of $167.0M and trades on NASDAQ.
- Who are Tenaya Therapeutics, Inc.'s competitors?
- Tenaya Therapeutics, Inc.'s key competitors include Sarepta Therapeutics, Lexeo Therapeutics, Rocket Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Tenaya Therapeutics, Inc. partner with?
- Tenaya Therapeutics, Inc.'s notable partners include Alnylam Pharmaceuticals, Inc., California Institute for Regenerative Medicine.
- Where is Tenaya Therapeutics, Inc. headquartered?
- Tenaya Therapeutics, Inc. is headquartered in United States of America and employs approximately 140 people. It has been publicly traded since 2021.